Collegium Pharmaceutical (COLL) Settles Patent Dispute with Grünenthal, Ending Royalty Obligations

gurufocus.com · 2026-10-19

On October 19, 2026, Collegium Pharmaceutical Inc. (NASDAQ: COLL) announced a settlement resolving its long-standing patent conflict with Grünenthal regarding

TickrTrends take: The settlement of Collegium Pharmaceutical's patent dispute with Grünenthal eliminates future royalty obligations, which should improve the company's cash flow profile going forward. TickrTrends currently rates COLL as undervalued, and resolution of this legal uncertainty removes a contingent liability that previously weighed on the company's financial trajectory. Investors monitoring the Healthcare sector should track whether this obligation elimination translates into expanded margins or accelerated profitability in upcoming quarters.

Read the full story at gurufocus.com →